Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jan 1;84(1):52–56. doi: 10.1054/bjoc.2000.1529

p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression

J Creaney 1, B M McLaren 1, S Stevenson 1, A W Musk 1, N de Klerk 1, B W S Robinson 1, R A Lake 1
PMCID: PMC2363614  PMID: 11139313

Abstract

Malignant mesothelioma (MM) generally occurs as a pleural tumour, related to the inhalation of asbestos fibres. It is highly aggressive and largely unresponsive to treatment. The incidence of MM is particularly high in Western Australia because of the extensive blue asbestos mining operations that occurred in the north of the state until 1966. MM is unusual in that mutations in the tumour suppressor gene p53 are rarely observed, whilst over-expression of p53 protein is common. As the level of antibodies directed against p53 is thought to be of prognostic value in some cancers and as MM is known to be immunogenic, we studied a cohort of Western Australian patients to determine the prevalence of anti-p53 antibodies and their value as diagnostic markers or prognostic indicators. 6/88 (7%) of patients had high titres (>2 SD above the mean of controls) of anti-p53 antibodies. There was no correlation between antibody titre and survival. Although 3/38 (8%) of sera obtained from patients exposed to asbestos but prior to a diagnosis of MM contained antibodies, the same proportion of sera obtained from patients exposed to asbestos but who remained disease free also contained antibodies (2/40; 8%). Sera collected sequentially demonstrated a profound temporal stability in the titre of anti-p53 antibodies in patients with MM throughout the course of their illness. These results show that anti-p53 antibodies are observed only at a low frequency in the sera of MM patients and where they do occur, their elicitation is an early event that may be unrelated to antigen load. The occurrence of anti-p53 antibodies does not serve as either a useful prognostic or diagnostic indicator in MM. © 2001 Cancer Research Campaign http://www.bjcancer.com

Full Text

The Full Text of this article is available as a PDF (107.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson M., Wallin H., Jönsson M., Nielsen L. L., Visfeldt J., Vyberg M., Bennett W. P., De Benedetti V. M., Travis L. B., Storm H. H. Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status. Int J Cancer. 1995 Nov 3;63(3):330–336. doi: 10.1002/ijc.2910630304. [DOI] [PubMed] [Google Scholar]
  2. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994 Aug 15;58(4):480–487. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  3. Ashcroft M., Vousden K. H. Regulation of p53 stability. Oncogene. 1999 Dec 13;18(53):7637–7643. doi: 10.1038/sj.onc.1203012. [DOI] [PubMed] [Google Scholar]
  4. Brass N., Rácz A., Bauer C., Heckel D., Sybrecht G., Meese E. Role of amplified genes in the production of autoantibodies. Blood. 1999 Apr 1;93(7):2158–2166. [PubMed] [Google Scholar]
  5. Carbone M., Fisher S., Powers A., Pass H. I., Rizzo P. New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol. 1999 Aug;180(2):167–172. doi: 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  6. Cheever M. A., Disis M. L., Bernhard H., Gralow J. R., Hand S. L., Huseby E. S., Qin H. L., Takahashi M., Chen W. Immunity to oncogenic proteins. Immunol Rev. 1995 Jun;145:33–59. doi: 10.1111/j.1600-065x.1995.tb00076.x. [DOI] [PubMed] [Google Scholar]
  7. Davidson J. A., Musk A. W., Wood B. R., Morey S., Ilton M., Yu L. L., Drury P., Shilkin K., Robinson B. W. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother. 1998 Sep;21(5):389–398. doi: 10.1097/00002371-199809000-00007. [DOI] [PubMed] [Google Scholar]
  8. Esposito V., Baldi A., De Luca A., Claudio P. P., Signoriello G., Bolognese A., Centonze P., Giordano G. G., Caputi M., Baldi F. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res. 1997 Jan-Feb;17(1B):733–736. [PubMed] [Google Scholar]
  9. Gansauge S., Gansauge F., Negri G., Galle P., Müller J., Nüssler A. K., Poch B., Beger H. G. The role of anti-p53-autoantibodies in pancreatic disorders. Int J Pancreatol. 1996 Jun;19(3):171–178. doi: 10.1007/BF02787365. [DOI] [PubMed] [Google Scholar]
  10. Gonin S., Diaz-Latoud C., Richard M. J., Ursini M. V., Imbo A., Manero F., Arrigo A. P. p53/T-antigen complex disruption in T-antigen transformed NIH3T3 fibroblasts exposed to oxidative stress: correlation with the appearance of a Fas/APO-1/CD95 dependent, caspase independent, necrotic pathway. Oncogene. 1999 Dec 23;18(56):8011–8023. doi: 10.1038/sj.onc.1203319. [DOI] [PubMed] [Google Scholar]
  11. Gottschlich S., Folz B. J., Goeroegh T., Lippert B. M., Maass J. D., Werner J. A. A new prognostic indicator for head and neck cancer--p53 serum antibodies? Anticancer Res. 1999 Jul-Aug;19(4A):2703–2705. [PubMed] [Google Scholar]
  12. Hammel P., Leroy-Viard K., Chaumette M. T., Villaudy J., Falzone M. C., Rouillard D., Hamelin R., Boissier B., Remvikos Y. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer. 1999 May 31;81(5):712–718. doi: 10.1002/(sici)1097-0215(19990531)81:5<712::aid-ijc7>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  13. Lai C. L., Tsai C. M., Tsai T. T., Kuo B. I., Chang K. T., Fu H. T., Perng R. P., Chen J. Y. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res. 1998 Dec;4(12):3025–3030. [PubMed] [Google Scholar]
  14. Lang C., Unteregger G., Kartarius S., Günther J., Bonkhoff H., Montenarh M., Zwergel T. p53 autoantibodies in patients with urological tumours. Br J Urol. 1998 Nov;82(5):721–726. doi: 10.1046/j.1464-410x.1998.00814.x. [DOI] [PubMed] [Google Scholar]
  15. Lechner J. F., Tesfaigzi J., Gerwin B. I. Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis. Environ Health Perspect. 1997 Sep;105 (Suppl 5):1061–1067. doi: 10.1289/ehp.97105s51061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lee W. C., Testa J. R. Somatic genetic alterations in human malignant mesothelioma (review). Int J Oncol. 1999 Jan;14(1):181–188. [PubMed] [Google Scholar]
  17. Lenner P., Wiklund F., Emdin S. O., Arnerlöv C., Eklund C., Hallmans G., Zentgraf H., Dillner J. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer. 1999 Feb;79(5-6):927–932. doi: 10.1038/sj.bjc.6690148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997 Feb 7;88(3):323–331. doi: 10.1016/s0092-8674(00)81871-1. [DOI] [PubMed] [Google Scholar]
  19. Lubin R., Schlichtholz B., Teillaud J. L., Garay E., Bussel A., Wild C. P. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res. 1995 Dec;1(12):1463–1469. [PubMed] [Google Scholar]
  20. Manning L. S., Whitaker D., Murch A. R., Garlepp M. J., Davis M. R., Musk A. W., Robinson B. W. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer. 1991 Jan 21;47(2):285–290. doi: 10.1002/ijc.2910470219. [DOI] [PubMed] [Google Scholar]
  21. Mayall F. G., Jacobson G., Wilkins R. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. J Clin Pathol. 1999 Apr;52(4):291–293. doi: 10.1136/jcp.52.4.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McLaren B. R., Haenel T., Stevenson S., Mukherjee S., Robinson B. W., Lake R. A. Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas. Aust N Z J Med. 2000 Aug;30(4):450–456. doi: 10.1111/j.1445-5994.2000.tb02050.x. [DOI] [PubMed] [Google Scholar]
  23. Metcalf R. A., Welsh J. A., Bennett W. P., Seddon M. B., Lehman T. A., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B. I. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992 May 1;52(9):2610–2615. [PubMed] [Google Scholar]
  24. Mitsudomi T., Suzuki S., Yatabe Y., Nishio M., Kuwabara M., Gotoh K., Hatooka S., Shinoda M., Suyama M., Ogawa M. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst. 1998 Oct 21;90(20):1563–1568. doi: 10.1093/jnci/90.20.1563. [DOI] [PubMed] [Google Scholar]
  25. Mor O., Yaron P., Huszar M., Yellin A., Jakobovitz O., Brok-Simoni F., Rechavi G., Reichert N. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol. 1997 Jan;16(1):9–13. doi: 10.1165/ajrcmb.16.1.8998073. [DOI] [PubMed] [Google Scholar]
  26. Murthy S. S., Testa J. R. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol. 1999 Aug;180(2):150–157. doi: 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  27. Musk A. W., de Klerk N. H., Ambrosini G. L., Eccles J. L., Hansen J., Olsen N. J., Watts V. L., Lund H. G., Pang S. C., Beilby J. Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. Int J Cancer. 1998 Jan 30;75(3):355–361. doi: 10.1002/(sici)1097-0215(19980130)75:3<355::aid-ijc5>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  28. Nakajima K., Suzuki T., Shimada H., Hayashi H., Takeda A., Ochiai T. Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumour Biol. 1999 May-Jun;20(3):147–152. doi: 10.1159/000030057. [DOI] [PubMed] [Google Scholar]
  29. Ramael M., Lemmens G., Eerdekens C., Buysse C., Deblier I., Jacobs W., van Marck E. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992 Dec;168(4):371–375. doi: 10.1002/path.1711680406. [DOI] [PubMed] [Google Scholar]
  30. Robinson C., Callow M., Stevenson S., Scott B., Robinson B. W., Lake R. A. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol. 2000 May;22(5):550–556. doi: 10.1165/ajrcmb.22.5.3930. [DOI] [PubMed] [Google Scholar]
  31. Robinson C., Robinson B. W., Lake R. A. Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer. 1998 Jun;20(3):175–184. doi: 10.1016/s0169-5002(98)00014-2. [DOI] [PubMed] [Google Scholar]
  32. Saffroy R., Lelong J. C., Azoulay D., Salvucci M., Reynes M., Bismuth H., Debuire B., Lemoine A. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer. 1999 Feb;79(3-4):604–610. doi: 10.1038/sj.bjc.6690095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schneider J., Presek P., Braun A., Bauer P., Konietzko N., Wiesner B., Woitowitz H. J. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer. 1999 Aug;80(12):1987–1994. doi: 10.1038/sj.bjc.6690632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ungar S., Van de Meeren A., Tammilehto L., Linnainmaa K., Mattson K., Gerwin B. I. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer. 1996 Nov;74(10):1534–1540. doi: 10.1038/bjc.1996.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Upham J. W., Musk A. W., van Hazel G., Byrne M., Robinson B. W. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med. 1993 Dec;23(6):683–687. doi: 10.1111/j.1445-5994.1993.tb04727.x. [DOI] [PubMed] [Google Scholar]
  36. Vogl F. D., Stickeler E., Weyermann M., Köhler T., Grill H. J., Negri G., Kreienberg R., Runnebaum I. B. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology. 1999 Nov;57(4):324–329. doi: 10.1159/000012069. [DOI] [PubMed] [Google Scholar]
  37. Wu C. W., Lin Y. Y., Chen G. D., Chi C. W., Carbone D. P., Chen J. Y. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer. 1999 May;80(3-4):483–488. doi: 10.1038/sj.bjc.6690382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. de Klerk N. H., Musk A. W., Ambrosini G. L., Eccles J. L., Hansen J., Olsen N., Watts V. L., Lund H. G., Pang S. C., Beilby J. Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. Int J Cancer. 1998 Jan 30;75(3):362–367. doi: 10.1002/(sici)1097-0215(19980130)75:3<362::aid-ijc6>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES